未经证实:原发性肺滑膜肉瘤(PPSS)极为罕见。本研究旨在确定决定PPSS生存的临床病理和治疗因素。
UNASSIGNED:我们对来自监测的121名患者进行了回顾性分析,流行病学,和最终结果数据库以及我们自己机构诊断为PPSS的12名患者。使用Kaplan-Meier方法评估患者的生存率。
UNASSIGNED:我们机构的12名PPSS患者的中位生存时间为78个月。术后化疗(总生存率P=.027,疾病特异性生存率P=.035)与高生存率相关,而肺切除术(总生存率P=.011,疾病特异性生存率P=.006)与较差的生存率相关.单叶受累(P=0.022)和无淋巴结受累(P=0.045)与改善疾病特异性生存率和总生存率相关,分别。在监视中,流行病学,和最终结果数据库,中位生存时间为23个月。在早期美国癌症联合委员会(Ⅰ-Ⅱ期)的患者中观察到明显优越的生存率(总生存率和疾病特异性生存率均P<.001)。在最近十年内被诊断的患者没有获得更好的生存率(总生存率P=.599,疾病特异性生存率P=.596)。
未经证实:PPSS具有侵袭性,预后极差。第七届美国癌症阶段联合委员会可能有助于预测生存率。肺切除术和淋巴结受累可能与更低的生存率有关。而单叶受累和术后化疗可能与生存率提高有关。
UNASSIGNED: Primary pulmonary synovial sarcoma (PPSS) is extremely rare. This study aims to identify the clinicopathologic and therapeutic factors determining survival in PPSS.
UNASSIGNED: We performed a retrospective analysis of 121 patients from the Surveillance, Epidemiology, and End Results Database as well as 12 patients from our own institution diagnosed with PPSS. Patient survival was evaluated using the Kaplan-Meier method.
UNASSIGNED: The median survival time for 12 PPSS patients in our institution was 78 months. Postoperative chemotherapy (P = .027 for overall survival and P = .035 for disease-specific survival) was associated with superior survival, whereas pneumonectomy (P = .011 for overall survival and P = .006 for disease-specific survival) was associated with worse survival. Single lobe involvement (P = .022) and the absence of lymph node involvement (P = .045) were associated with improved disease-specific survival and overall survival, respectively. In the Surveillance, Epidemiology, and End Results Database, the median survival time was 23 months. Significantly superior survival was observed in patients with earlier American Joint Committee on Cancer stage (Ⅰ-Ⅱ) (P < .001 for both overall survival and disease-specific survival). Patients who were diagnosed within the recent decade did not achieve a better survival (P = .599 for overall survival and P = .596 for disease-specific survival).
UNASSIGNED: PPSS was aggressive with a very poor prognosis. The seventh American Joint Committee on Cancer stage might aid in predicting survival. Pneumonectomy and lymph node involvement might be associated with worse survival, whereas single lobe involvement and postoperative chemotherapy might be associated with improved survival.